Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M, Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.

Objective:

Vitamin E is frequently used to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). However, the response to vitamin E-related treatments in improving liver function and histology in NAFLD/NASH had not been systematically quantified. A meta-analysis of controlled trials was therefore conducted to examine the efficacy of vitamin E for NAFLD/NASH.

Results:

Across five studies, vitamin E significantly reduced AST (aspartate transaminase) by 19.43 U/L, ALT (alanine transaminase) by 28.91 U/L and ALP (alkaline phosphatase) by 10.39 U/L.

It contributed to reductions in steatosis (fat accumulation in the liver) of 0.54 U/L and inflammation levels of 0.20 U/L compared with the control group.

In addition to these findings, vitamin E treatment in adults with NASH showed a clear reduction in fibrosis compared with the control group.

Conclusions:

Vitamin E significantly improved liver function and histological changes in patients with NAFLD/NASH.

Leave a Reply